MedTrace Logo

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 801

Last updated 2025-06-22

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

Conditions

  • Measles; Mumps; Rubella; Chickenpox
  • Measles

Interventions

BIOLOGICAL

Investigational MMRV(H)NS vaccine

1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.

BIOLOGICAL

Investigational MM(H)RVNS vaccine

1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.

BIOLOGICAL

Investigational M(L)M(L)R(L)V(L)NS vaccine

1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.

BIOLOGICAL

Marketed MMRV_Lot 1 and Lot 2 vaccine

1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-14
Primary Completion
2024-06-07
Completion
2024-10-14
FDA Drug
Yes

Countries

  • United States
  • Colombia
  • Latvia
  • Puerto Rico
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630846 on ClinicalTrials.gov